Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117161) titled 'Prospective Phase II Single-Arm Study of Induction Therapy with Aumolertinib and Chemotherapy in Potentially Resectable Stage ? EGFR-Mutant Non-Squamous NSCLC' on Jan. 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sichuan Cancer Hospital
Condition:
Non-small cell lung cancer
Intervention:
Experimental group:After three cycles of treatment with aumolertinib combined with pemetrexed + carboplatin, treatment efficacy will be assessed.
Aumolertinib is administered at 110 mg orally once daily (po qd)
pemetrexed at 500 mg/m2, and carboplatin at an area under the curve (AUC) of 4-...